At 7.6% CAGR, the Asia Pacific CIN & HR-HPV Treatment Market is projected to be worth US$ 3,949.99 million by 2028, says The Business Market Insights

According to the Business Market Insights’ research, the Asia Pacific CIN & HR-HPV treatment market was valued at US$ 2,738.94 million in 2023 and is expected to reach US$ 3,949.99 million by 2028, registering a CAGR of 7.6% from 2023 to 2028.

Development and launch of innovative products and use of modern technologies in CIN & HR-HPV screening and diagnosis are the critical factors attributed to the Asia Pacific CIN & HR-HPV treatment market expansion.                    

Companies in the healthcare market are undertaking various research and development activities to introduce advanced tests for HPV diagnosis. In May 2021, BD, a leading medical technology company, launched the first CE-marked assay for HPV screening from at-home self-collected vaginal samples. This allows laboratories to process self-collected samples through a BD diluent tube using BD Onclarity HPV assay. The at-home collection of samples helps address the urgent public health challenge of reaching out to women who do not attend routine cervical cancer screening.

On the contrary, Increased reoccurrence rate and high cost of CIN & HR-HPV treatment devices hurdle the growth of Asia Pacific CIN & HR-HPV treatment market.

Based on disease type, the Asia Pacific CIN & HR-HPV treatment market is segmented into cervical intraepithelial neoplasia 1 (CIN 1), cervical intraepithelial neoplasia 2 (CIN 2), and cervical intraepithelial neoplasia 3 (CIN 3). The cervical intraepithelial neoplasia 3 (CIN 3) segment held 49.0% market share in 2023, amassing US$ 1,342.32 million. It is projected to garner US$ 2,014.65 million by 2028 to expand at 8.5% CAGR during 2023–2028.

Based on strain type, the Asia Pacific CIN & HR-HPV treatment market is segmented into HPV 16, HPV 18, and others. The HPV 16 segment held 62.7% market share in 2023, amassing US$ 1,717.88 million. It is projected to garner US$ 2,481.69 million by 2028 to expand at 7.6% CAGR during 2023–2028.

Based on offering, the Asia Pacific CIN & HR-HPV treatment market is bifurcated into diagnostic methods and treatments. The treatments segment held 72.6% market share in 2023, amassing US$ 1,988.54 million. It is projected to garner US$ 2,794.29 million by 2028 to expand at 7.0% CAGR during 2023–2028. Further, diagnostic methods are segmented into pap smear, HPV testing, colposcopy, and biopsy. Further, treatments are bifurcated into excision surgery and ablation techniques.

Based on product type, the Asia Pacific CIN & HR-HPV treatment market is segmented into kits & reagents, instruments, and services. The services segment held 57.2% market share in 2023, amassing US$ 1,566.70 million. It is projected to garner US$ 2,269.42 million by 2028 to expand at 7.7% CAGR during 2023–2028.

Based on end user, the Asia Pacific CIN & HR-HPV treatment market is segmented into hospitals & clinics, diagnostic laboratories, specialized clinical laboratories, and others. The hospitals & clinics segment held 52.6% market share in 2023, amassing US$ 1,441.42 million. It is projected to garner US$ 2,060.06 million by 2028 to expand at 7.4% CAGR during 2023–2028.

Based on country, the Asia Pacific CIN & HR-HPV treatment market has been categorized into China, India, Japan, South Korea, Australia, and the Rest of APAC.  Our regional analysis states that China captured 38.9% market share in 2023. It was assessed at US$ 1,064.49 million in 2023 and is likely to hit US$ 1,549.98 million by 2028, exhibiting a CAGR of 7.8% during the forecast period.     

Key players dominating the Asia Pacific CIN & HR-HPV treatment are Fujirebio Europe NV; Qiagen NV; Abbott Laboratories; F. Hoffmann-LA Roche Ltd; Bioneer Corp; and Thermo Fisher Scientific Inc among others.   

• In Oct 2022, Fujirebio Europe receives distribution rights  
• In April 2021, Roche receives FDA approval for cobas HPV test.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com